Abstract
Idiopathic Parkinsons Disease (PD) is a progressive neurodegenerative disease characterized by dopaminergic neuronal loss within the substantia nigra. The degeneration of dopamine and other neuronal populations in PD lead to both chronic motor and non-motor disabilities but the mechanisms remain unclear. Molecular genetic studies in familial forms of the disease identified key proteins involved in PD pathogenesis, supporting a major role for (i) protein aggregation and neurotoxic α-synuclein oligomeric species due to an altered protein quality control, (ii) parkin-driven deregulation of the ubiquitin-proteasome system, (iii) oxidative stress and mithocondrial dysfunction, and, finally, (iv) disturbed kinase activity. The elucidation of these new molecular pathways has increased our knowledge of PD pathophysiology, but it remains an open question whether alterations of these pathways lead to different entities of PD or whether they finally converge at a point that is the common pathogenetic denominator of PD. However, the knowledge of validated targets is in its infancy, and thus, traditional target-based drug discovery strategies are of limited use. Alternative approaches are needed, and early attempts were aimed at identifying molecules inhibiting the aggregation of α-synuclein fragments, interfering with the ubiquitin proteasome pathway and reducing oxidative stress. Such discovery strategies have an impact on the configuration of screening cascades for effective translation of drug candidates toward clinical trials. This review examines how these genetic findings provided us with suitable animal models and how the gained insights will contribute to better therapies for PD.
Keywords: Parkinson's disease, ubiquitin-proteasome system, parkin, autophagy, α-Synuclein, UCH-L1 (ubiquitin carboxyterminal hydrolase L1), DJ-1, Pink1 (PTEN-induced kinase 1), Leucine-rich repeat kinase 2 (LRRK2), Dopaminergic neurons
Current Topics in Medicinal Chemistry
Title: New Molecular Avenues in Parkinson ’ s Disease Therapy
Volume: 9 Issue: 10
Author(s): Mario Di Napoli
Affiliation:
Keywords: Parkinson's disease, ubiquitin-proteasome system, parkin, autophagy, α-Synuclein, UCH-L1 (ubiquitin carboxyterminal hydrolase L1), DJ-1, Pink1 (PTEN-induced kinase 1), Leucine-rich repeat kinase 2 (LRRK2), Dopaminergic neurons
Abstract: Idiopathic Parkinsons Disease (PD) is a progressive neurodegenerative disease characterized by dopaminergic neuronal loss within the substantia nigra. The degeneration of dopamine and other neuronal populations in PD lead to both chronic motor and non-motor disabilities but the mechanisms remain unclear. Molecular genetic studies in familial forms of the disease identified key proteins involved in PD pathogenesis, supporting a major role for (i) protein aggregation and neurotoxic α-synuclein oligomeric species due to an altered protein quality control, (ii) parkin-driven deregulation of the ubiquitin-proteasome system, (iii) oxidative stress and mithocondrial dysfunction, and, finally, (iv) disturbed kinase activity. The elucidation of these new molecular pathways has increased our knowledge of PD pathophysiology, but it remains an open question whether alterations of these pathways lead to different entities of PD or whether they finally converge at a point that is the common pathogenetic denominator of PD. However, the knowledge of validated targets is in its infancy, and thus, traditional target-based drug discovery strategies are of limited use. Alternative approaches are needed, and early attempts were aimed at identifying molecules inhibiting the aggregation of α-synuclein fragments, interfering with the ubiquitin proteasome pathway and reducing oxidative stress. Such discovery strategies have an impact on the configuration of screening cascades for effective translation of drug candidates toward clinical trials. This review examines how these genetic findings provided us with suitable animal models and how the gained insights will contribute to better therapies for PD.
Export Options
About this article
Cite this article as:
Di Napoli Mario, New Molecular Avenues in Parkinson ’ s Disease Therapy, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378254
DOI https://dx.doi.org/10.2174/156802609789378254 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry LHON: Mitochondrial Mutations and More
Current Genomics Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Cholesterol in Alzheimers Disease: Unresolved Questions
Current Alzheimer Research <i>In Vitro</i> Screening for Cytotoxic, Anti-bacterial, Anti-HIV1-RT Activities and Chemical Constituents of <i>Croton fluviatilis, Croton acutifolius</i>, and <i>Croton thorelii</i>
The Natural Products Journal Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Practical Issues in Stem Cell Therapy for Alzheimers Disease
Current Alzheimer Research Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Gene Transfer with Sequence-Defined Oligo(ethanamino)amides Bioreducibly Attached to a Propylenimine Dendrimer Core
Pharmaceutical Nanotechnology Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Differential Regulation of Neurotoxin in HIV Clades: Role of Cocaine and Methamphetamine
Current HIV Research